Arkin Bio Ventures led a $41m Series B round in Bluejay Therapeutics.

Arkin Bio Ventures, a healthcare investment company, led a $41m Series B round in Bluejay Therapeutics, a virology and liver disease-based company, with participation from other Synergenics, RiverVest Venture Partners, Yonjin Capital, Octagon Capital and InnoPinnacle International. “Bill and Alon’s extensive experience across therapeutic areas will be invaluable to Bluejay at this time of growth for our company. We are very excited to have them on the team," Dr. Keting Chu, Bluejay Therapeutics Founder, Chairman and CEO.